<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">24800899</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-2072</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>231</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Psychopharmacology</Title>
          <ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The activation of the Akt/PKB signalling pathway in the brains of clozapine-exposed rats is linked to hyperinsulinemia and not a direct drug effect.</ArticleTitle>
        <Pagination>
          <StartPage>4553</StartPage>
          <EndPage>4560</EndPage>
          <MedlinePgn>4553-60</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-014-3608-0</ELocationID>
        <Abstract>
          <AbstractText>The second generation antipsychotic drug clozapine is a much more effective therapy for schizophrenia than first generation compounds, but the reasons for this are poorly understood. We have previously shown that one distinguishing feature of clozapine is its ability to raise glucagon levels in animal models and thus causes prolonged hyperinsulinemia without inducing hypoglycaemia. Previous studies have provided evidence that defects in Akt/PKB and GSK3 signalling can contribute to development of psychiatric diseases. Clozapine is known to activate Akt/PKB in the brain, and some studies have indicated that this is due to a direct effect of the drug on the neurons. However, we provide strong evidence that elevated insulin levels induced by clozapine are in fact the real cause of the drug's effects on Akt/PKB and GSK3 in the brain. This suggests that the elevated levels of insulin induced by clozapine may contribute to this drug's therapeutic efficacy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>G C</ForeName>
            <Initials>GC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, g.smith@unsw.edu.au.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McEwen</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steinberg</LastName>
            <ForeName>J D</ForeName>
            <Initials>JD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shepherd</LastName>
            <ForeName>P R</ForeName>
            <Initials>PR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Psychopharmacology (Berl)</MedlineTA>
        <NlmUniqueID>7608025</NlmUniqueID>
        <ISSNLinking>0033-3158</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J60AR2IKIC</RegistryNumber>
          <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006946" MajorTopicYN="N">Hyperinsulinism</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24800899</ArticleId>
        <ArticleId IdType="doi">10.1007/s00213-014-3608-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Neuropsychopharmacology. 2006 Apr;31(4):853-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16205782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12615961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell Endocrinol. 2001 May 25;177(1-2):125-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11377828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Neuropsychopharmacol. 2007 Feb;10(1):7-19</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16672106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Ther. 2012 Oct;136(1):82-93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22820012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurochem. 2005 Oct;95(2):513-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16144542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res. 2004 Jun 11;1011(1):58-68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15140644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2012;7(8):e43244</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22905238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trends Neurosci. 2007 Apr;30(4):142-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17324475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur Neuropsychopharmacol. 2002 Feb;12(1):13-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11788236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 1997 Aug 1;272(31):19547-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9235959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Neurobiol. 1989 Spring-Summer;3(1-2):71-100</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2553069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Mol Neurobiol. 2003 Feb;23(1):1-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12701881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Clin Nutr. 1999 Apr;69(4):584-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10197558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophr Res. 2009 Nov;115(1):30-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19679451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophr Res. 2008 Aug;103(1-3):94-103</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18579346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Genet. 2004 Feb;36(2):131-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14745448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Ther. 2006 Apr;110(1):117-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16434104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetologia. 1996 Nov;39(11):1392-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8933010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuropsychopharmacology. 2005 Jul;30(7):1223-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15827567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biochem J. 1998 Aug 1;333 ( Pt 3):471-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9677303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FEBS Lett. 2004 Feb 27;560(1-3):115-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14988008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychoneuroendocrinology. 2003 Aug;28(6):809-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12812866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Drug Targets. 2006 Nov;7(11):1421-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17100582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Neurol. 2006 Jan;5(1):64-74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16361024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuroscience. 1991;42(3):853-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1720228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2001 Feb 16;276(7):5256-64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11054421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Mol Neurosci. 2005;27(1):43-64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16055946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophr Res. 2006 May;84(1):1-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16581231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocrinology. 1990 Dec;127(6):3234-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2249648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurochem. 2005 Aug;94(4):1158-66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16092951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peptides. 2002 Dec;23(12):2283-306</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12535710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biol Psychiatry. 2005 Mar 1;57(5):533-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15737669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res. 1983 Feb 7;260(2):330-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6339003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharmacol Exp Ther. 2003 May;305(2):625-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12606608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neural Transm (Vienna). 2004 Jun;111(6):667-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15168214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetologia. 2008 Dec;51(12):2309-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18843478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Physiol Biochem. 2011 Oct;117(4):241-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21671852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 1978 Nov;75(11):5737-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">364489</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
